Understanding Medication Waste When Switching MS Treatments

Credibility

Interest

Key Takeaway

Switching medications for MS can lead to a lot of wasted medicine and extra costs for both patients and insurers.

What They Found

Many people with MS often change their treatments, which is known as disease-modifying therapies (DMTs). When they switch, they sometimes have leftover medicine that they can't use, which means it's wasted. This waste can cost insurers and patients a lot of money—over $1 million in just a year! About 95% of patients switched treatments at least once, and some wasted about a third of their previous medication. This means that patients still had to pay a good amount, even if most of the costs were covered by insurance.

Who Should Care and Why

MS patients and their caregivers should care about this study because it highlights the financial impact of switching treatments. Imagine buying a new phone but still having to pay for the old one you can't use anymore; that's how wasted medication feels. Understanding these costs can help patients make smarter choices about their treatments. Caregivers can also help by keeping track of medications and making sure their loved ones use them effectively. This way, they can save money and reduce waste, leading to better care and less stress.

Important Considerations

The study looked at specific data from 2017 to 2021, which means the results may not capture more recent trends or changes in medications. It also focused only on those who switched treatments, so not all MS patients were included. These limitations are important because they show that while the findings are significant, they might not apply to everyone with MS.

Categories:

Living with MS Mental Wellness Caregivers

Article Topics:

costdisease-modifying therapiesmedication wastagemultiple sclerosissite of service

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of health economics and outcomes research often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News